Physician profile
Lukas Jantac
NPI 1750507463
$11,218.56
in general payments reported to CMS, 2019-2025
37 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,107 · 2020: $672 · 2021: $1,773 · 2022: $1,545 · 2023: $1,834 · 2024: $2,225 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,121.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,505.61 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $1,198.63 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,001.02 | 2019-2025 | Wainua, Farxiga |
| Sanofi-Aventis U.S. LLC | $754.21 | 2019-2024 | |
| Boston Scientific Corporation | $735.41 | 2021-2025 | Watchman Flx, Watchman Access System, Bodyguardian |
| Janssen Pharmaceuticals, INC | $715.59 | 2019-2024 | Xarelto |
| Amgen INC. | $585.94 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $548.43 | 2021-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $505.47 | 2019-2025 | |
| Esperion Therapeutics, INC. | $499.66 | 2020-2024 | Nexletol, Nexlizet |
| Amarin Pharma, INC. | $423.98 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $356.59 | 2019-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $345.82 | 2021-2025 | |
| Novo Nordisk INC | $323.58 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $286.64 | 2022-2025 | Camzyos, Eliquis |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lukas Jantac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.